Table 3.
CD4 count (cells/ml) | Treatment | |||||||||||
# | Age, sex | Symptoms | Organ involvement | Diagnostic procedure | Baseline viral loada | Baselineb | At time of IRIS | At time of follow upc | Viral load at follow up | Time to IRISd (days) | MAC therapy | Duration of corticosteroid (months) |
1 | 37, F | Fever, N/V | GI, liver | Liver biopsy | 249,880 | 10 | 54 | 84 | <50 | 226 | Azm, ETB | 12 |
2 | 40, M | Fever, abd pain | Abd LN | LN aspirate | 32,318 | 43 | 165 | 229 | <50 | 66 | Azm, ETB | --- |
3 | 44, M | Fever, abd pain | GI, Bone marrow | BMBx, blood Cx | 215,201 | 69 | 199 | 326 | <50 | 25 | Clm, ETB, RIB, cipro | 22 |
4 | 59, M | Fever, abd pain | GI, Bone marrow | GI biopsy, BMBx | 188,000 | 34 | 98 | 140 | <50 | 604 | Azm, ETB, RIB, cipro | 10 |
5 | 33, M | LAN | Axillary LN | LN aspirate | 72,777 | 20 | 64 | 89 | <50 | 1689 | Clm, ETB | --- |
6 | 53, M | LAN | Axillary LN | Tissue culture | 750,000 | 9 | 111 | 201 | <50 | 306 | Clm, ETB | --- |
7 | 53, M | Fever, rash, NS | Supraclavicular LN | LN aspirate | 31,517 | 5 | 142 | 97 | <50 | 192 | Azm, ETB, RIB | --- |
8 | 47, M | Fever, abd pain, NS | Supraclavicular LN, Liver | Liver biopsy | 500,000 | 2 | 3 | 13 | 21,439 | 122 | Azm, ETB, RIB | Not available |
9 | 32, M | LAN | Cervical LN | LN aspirate | 117,580 | 204 | 224 | 403 | <50 | 456 | Clm, ETB, RIB | --- |
10 | 28, M | LAN | Axillary LN | Tissue culture | 217,174 | 8 | 66 | 226 | <50 | 75 | Clm, ETB, RIB | --- |
11 | 38, M | Fever, Wt loss | Liver, Bone marrow | Liver Bx, BMBx | 750,000 | 4 | 35 | 99 | 87 | 10 | Clm, ETB | --- |
12 | 38, M | Fever, LAN, fatigue | Cervical LN | Tissue culture | 366,000 | 16 | 46 | 10 | 97,000 | 18 | Azm, ETB, RIB | --- |
13 | 40, M | Fever, abd pain, N/V, diarrhea | Abd LN, GI | LN aspirate | 321,851 | 21 | 71 | 73 | 849 | 84 | Azm, ETB | 6 |
14 | 40, M | Fever, diarrhea, cough | ABD LN, Mediastinal LN | Blood Cx, CT | 624,697 | 1 | 18 | 48 | <50 | 63 | Clm, ETB, RIB | 14 |
15 | 30, F | Fever, NS, diarrhea | GI, Bone marrow | Tissue Bx, BMBx | 205,115 | 9 | 39 | 141 | 336 | 16 | Clm, ETB | --- |
16 | 42, F | Fever, NS | Abd LN | Blood Cx, CT | 2,115,623 | 7 | 65 | 118 | 2,729 | 17 | Clm, ETB | --- |
17 | 46, M | LAN, abd pain | Abd LN, supraclavicular LN, mediastinal LN | LN aspirate | 292,571 | 11 | 72 | 108 | <50 | 359 | Azm, ETB, RIB, cipro, amikacin | --- |
18 | 44, M | Fever, abd pain | Abd LN | LN aspirate | 205,000 | 5 | 61 | 40 | <50 | 360 | Clm, ETB, RIB, cipro, amikacin | 48 |
19 | 27, M | Fever, abd pain, N/V | GI, abd LN | Blood Cx, CT | 490,668 | 6 | 112 | 111 | <50 | 47 | Azm, ETB | 7 |
20 | 35, M | Fever, abd pain, N/V, diarrhea | GI, abd LN | Blood Cx, stool Cx, CT | 48,053 | 2 | 364 | 3 | 70,324 | 13 | Azm, ETB | --- |
Note: N/V, nausea and vomiting; abd, abdominal; LAN, lymphadenopathy; NS, night sweats; GI, gastrointestinal tract; LN, lymph node; Cx, culture; BMBx, bone marrow biopsy; Bx, biopsy; CT, CAT scan findings; Azm, azithromycin; ETB, ethambutol; Clm, clarithromycin; RIB, rifabutin.
a HIV quantitative PCR measured as copies/cc of plasma.
b CD4 count prior to the initiation of HAART.
c For responders, follow up = resolution of symptoms.
d Duration of time from the initiation of HAART to the development of IRIS symptoms.